Veracyte Ramps up Clinical Evidence Generation, Driving Gains in Prostate and Thyroid Test Business
360Dx,
NEW YORK – As evidence gathers, supporting the clinical value of its tests, Veracyte on Wednesday reported a 19 percent year…
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials
Overview of attention for article published in International Journal of Radiation Oncology, Biology, Physics, December 2022
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
High Attention Score compared to outputs of the same age and source (92nd percentile)
Readers on
- mendeley
- 43 Mendeley
